Supernus Pharmaceuticals, Inc.
Clinical trials sponsored by Supernus Pharmaceuticals, Inc., explained in plain language.
A pharmaceutical company specializing in central nervous system (CNS) treatments, including epilepsy and ADHD.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- ADHD drug SPN-812 tested for Long-Term safety in children Results expected Sep 2026 (estimated)
- New depression pill shows promise in Mid-Stage trial Results expected Dec 2026 (estimated)
- Parkinson's pump study tracks Real-Life symptom control Results expected Aug 2027 (estimated)
- New drug SPN-817 aims to tame Hard-to-Control seizures Results expected Aug 2027 (estimated)
-
Huntington's drug safety study halted early
Disease control Stopped earlyThis study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Migraine prevention drug trial in kids halted early
Prevention Stopped earlyThis study tested a drug called SPN-538 to prevent migraines in children aged 6 to 11. The trial was a randomized, double-blind, placebo-controlled study, meaning some children got the drug and some got a placebo. However, the study was terminated early and only enrolled 26 parti…
Phase 4 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC